$ADMA
ADMA Biologics Inc Stock $adma

$adma Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000119380521000411 Filed on March 25, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$13.96M	$42.22M	$12.04M
YoY Change	15.95%	43.85%	196.55%
Cost Of Revenue	$19.11M	$61.29M	$11.69M
YoY Change	63.47%	55.15%	4.94%
Gross Profit	-$5.160M	-$19.07M	$350.0K
YoY Change	-1574.29%	87.8%	-104.94%
Gross Profit Margin	-36.96%	-45.17%	2.91%
Selling, General & Admin	$10.87M	$35.05M	$7.500M
YoY Change	44.93%	24.82%	-20.21%
% of Gross Profit			2142.86%
Research & Development	$1.010M	$5.907M	$460.0K
YoY Change	119.57%	152.02%	-428.57%
% of Gross Profit			131.43%
Depreciation & Amortization	$1.230M	$3.200M	$830.0K
YoY Change	48.19%	33.33%	-10.75%
% of Gross Profit			237.14%
Operating Expenses	$12.06M	$45.84M	$8.170M
YoY Change	47.61%	-35.23%	-13.64%
Operating Profit	-$17.22M	-$64.91M	-$7.820M
YoY Change	120.2%	56.71%	-52.75%
Interest Expense	-$3.090M	$11.99M	-$2.550M
YoY Change	21.18%	33.27%	84.78%
% of Operating Profit
Other Income/Expense, Net	-$90.00K	-$10.83M	-$190.0K
YoY Change	-52.63%	58.04%	72.73%
Pretax Income	-$19.41M	-$75.75M	-$10.56M
YoY Change	83.81%	56.9%	-41.46%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$19.41M	-$75.75M	-$10.56M
YoY Change	83.81%	56.9%	-41.46%
Net Earnings / Revenue	-139.04%	-179.41%	-87.71%
Basic Earnings Per Share		-$0.88
Diluted Earnings Per Share	-$200.7K	-$0.88	-$177.9K
COMMON SHARES
Basic Shares Outstanding	94.55M shares	86.15M
Diluted Shares Outstanding		86.15M

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$55.90M	$55.90M	$26.80M
YoY Change	108.58%	108.58%	17.54%
Cash & Equivalents	$55.92M	$55.90M	$26.75M
Short-Term Investments
Other Short-Term Assets	$3.000M	$3.000M	$2.500M
YoY Change	20.0%	20.0%	38.89%
Inventory	$81.54M	$81.50M	$53.06M
Prepaid Expenses
Receivables	$13.24M	$13.20M	$3.470M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$153.7M	$153.7M	$85.82M
YoY Change	79.14%	79.14%	92.85%
LONG-TERM ASSETS
Property, Plant & Equipment	$41.59M	$45.90M	$31.74M
YoY Change	31.04%	38.67%	5.45%
Goodwill	$3.500M		$3.530M
YoY Change	-0.84%
Intangibles	$2.444M		$3.159M
YoY Change	-22.64%
Long-Term Investments
YoY Change
Other Assets	$2.100M	$2.100M	$2.800M
YoY Change	-25.0%	50.0%	-58.21%
Total Long-Term Assets	$53.93M	$54.00M	$41.27M
YoY Change	30.68%	30.75%	-7.05%
TOTAL ASSETS
Total Short-Term Assets	$153.7M	$153.7M	$85.82M
Total Long-Term Assets	$53.93M	$54.00M	$41.27M
Total Assets	$207.7M	$207.7M	$127.1M
YoY Change	63.41%	63.41%	42.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.07M	$11.10M	$9.175M
YoY Change	20.7%	20.65%	55.5%
Accrued Expenses	$8.365M	$8.700M	$4.481M
YoY Change	86.66%	85.11%	24.48%
Deferred Revenue	$142.8K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$19.95M	$19.90M	$14.03M
YoY Change	42.2%	42.14%	46.12%
LONG-TERM LIABILITIES
Long-Term Debt	$93.00M	$93.00M	$83.20M
YoY Change	11.78%	11.78%	88.66%
Other Long-Term Liabilities	$54.89K	$6.500M	$106.6K
YoY Change	-48.5%	75.68%	-99.31%
Total Long-Term Liabilities	$54.89K	$99.50M	$106.6K
YoY Change	-48.5%	14.5%	-99.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.95M	$19.90M	$14.03M
Total Long-Term Liabilities	$54.89K	$99.50M	$106.6K
Total Liabilities	$119.4M	$119.4M	$100.9M
YoY Change	18.36%	18.33%	46.02%
SHAREHOLDERS EQUITY
Retained Earnings	-$340.5M		-$264.7M
YoY Change	28.61%
Common Stock	$10.49K		$5.932K
YoY Change	76.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$88.25M	$88.20M	$26.19M
YoY Change
Total Liabilities & Shareholders Equity	$207.7M	$207.7M	$127.1M
YoY Change	63.41%	63.41%	42.96%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$19.41M	-$75.75M	-$10.56M
YoY Change	83.81%	56.9%	-41.46%
Depreciation, Depletion And Amortization	$1.230M	$3.200M	$830.0K
YoY Change	48.19%	33.33%	-10.75%
Cash From Operating Activities	-$32.22M	-$102.0M	-$19.65M
YoY Change	63.97%	33.87%	4.58%
INVESTING ACTIVITIES
Capital Expenditures	-$3.600M	$12.73M	-$1.590M
YoY Change	126.42%	233.87%	93.9%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$3.590M	-$12.72M	-$1.590M
YoY Change	125.79%	233.82%	93.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$131.2M
YoY Change		171.08%
Debt Paid & Issued, Net		$13.95M
YoY Change		-53.5%
Cash From Financing Activities	32.07M	143.9M	-10.00K
YoY Change	-320800.0%	79.86%
NET CHANGE
Cash From Operating Activities	-32.22M	-102.0M	-19.65M
Cash From Investing Activities	-3.590M	-12.72M	-1.590M
Cash From Financing Activities	32.07M	143.9M	-10.00K
Net Change In Cash	-3.740M	29.17M	-21.25M
YoY Change	-82.4%	-1073674.42%	8.36%
FREE CASH FLOW
Cash From Operating Activities	-$32.22M	-$102.0M	-$19.65M
Capital Expenditures	-$3.600M	$12.73M	-$1.590M
Free Cash Flow	-$28.62M	-$114.7M	-$18.06M
YoY Change	58.47%	43.4%	0.5%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	121275357	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55921152	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26752135	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13237290	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	81535599	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3046466	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	153740507	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41593090	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2444121	USD
CY2020Q4	us-gaap	Goodwill Goodwill	3529509	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4259191	USD
CY2020Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2106976	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3469919	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53064734	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2533593	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	85820381	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31741317	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3159474	USD
CY2019Q4	us-gaap	Goodwill Goodwill	3529509	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1245029	USD
CY2019Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1595015	USD
CY2019Q4	us-gaap	Assets Assets	127090725	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9174591	USD
CY2020Q4	us-gaap	Liabilities Liabilities	119423968	USD
CY2019Q4	adma	Lease Obligations Current LeaseObligationsCurrent	229073	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14027893	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	68291163	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2261532	USD
CY2020Q4	adma	Lease Obligations Noncurrent LeaseObligationsNoncurrent	4334151	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	54886	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	10490	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	428704039	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-340465103	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	88249426	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	207673394	USD
CY2020Q4	us-gaap	Assets Assets	207673394	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11073708	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8365143	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4481395	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142834	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	142834	USD
CY2020Q4	adma	Lease Obligations Current LeaseObligationsCurrent	365682	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19947367	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	92968866	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2118698	USD
CY2020Q4	us-gaap	Subordinated Debt SubordinatedDebt	0	USD
CY2019Q4	us-gaap	Subordinated Debt SubordinatedDebt	14908053	USD
CY2019Q4	adma	Lease Obligations Noncurrent LeaseObligationsNoncurrent	1302361	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106574	USD
CY2019Q4	us-gaap	Liabilities Liabilities	100897576	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	104902888	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59318355	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	5932	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	290903772	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-264716555	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	26193149	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	127090725	USD
CY2020	adma	Product Revenue ProductRevenue	42076949	USD
CY2019	adma	Product Revenue ProductRevenue	29206249	USD
CY2020	adma	License Revenue LicenseRevenue	142834	USD
CY2019	adma	License Revenue LicenseRevenue	142834	USD
CY2020	us-gaap	Revenues Revenues	42219783	USD
CY2019	us-gaap	Revenues Revenues	29349083	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	61291426	USD
CY2019	us-gaap	Cost Of Revenue CostOfRevenue	39504238	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5907013	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2343848	USD
CY2020	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	4170051	USD
CY2019	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2169629	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	715353	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	844938	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35050817	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25910757	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	107134660	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	70773410	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-64914877	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-41424327	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	288126	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	800785	USD
CY2020	us-gaap	Interest Expense InterestExpense	11985066	USD
CY2019	us-gaap	Interest Expense InterestExpense	8993379	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	991797	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9962495	USD
CY2020	adma	Gain On Transfer Of Plasma Center Assets GainOnTransferOfPlasmaCenterAssets	0	USD
CY2019	adma	Gain On Transfer Of Plasma Center Assets GainOnTransferOfPlasmaCenterAssets	11527421	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2855122	USD
CY2020	adma	Warrants Issued In Connection With Note Payable WarrantsIssuedInConnectionWithNotePayable	3740980	USD
CY2020	adma	Vesting Of Restricted Stock Units Amount VestingOfRestrictedStockUnitsAmount	0	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3401815	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-128528	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-227322	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10833671	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6854990	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75748548	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-48279317	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86145052	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54348136	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	19770438	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2650777	USD
CY2019	adma	Warrants Issued In Connection With Note Payable WarrantsIssuedInConnectionWithNotePayable	3579115	USD
CY2019	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	48397088	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	75048	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-48279317	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	26193149	USD
CY2020	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	131195291	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13432	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75748548	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	88249426	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-75748548	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-48279317	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3942292	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3258148	USD
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	81697	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	207071	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2855122	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2650777	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1782428	USD
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1180348	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	991797	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-9962495	USD
CY2020	adma	Gain On Transfer Of Plasma Center Assets GainOnTransferOfPlasmaCenterAssets	0	USD
CY2020	adma	Amortization Of License Revenue AmortizationOfLicenseRevenue	-142834	USD
CY2019	adma	Amortization Of License Revenue AmortizationOfLicenseRevenue	-142834	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9767371	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2077478	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-28470864	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-34650132	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-512873	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-773174	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-196749	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	107974	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1899115	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3274200	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	806353	USD
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-134391	USD
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-190514	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-102002958	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76193504	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12726680	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3811838	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12724680	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3811838	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	13950000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	30000000	USD
CY2020	us-gaap	Payments For Fees PaymentsForFees	0	USD
CY2019	us-gaap	Payments For Fees PaymentsForFees	2760000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	131195291	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	48397088	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13432	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	75048	USD
CY2020	adma	Payment Of Debt Refinancing Fees PaymentOfDebtRefinancingFees	-830000	USD
CY2019	adma	Payment Of Debt Refinancing Fees PaymentOfDebtRefinancingFees	-6499867	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	27500000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	72500000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1679661	USD
CY2020	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	32068	USD
CY2019	us-gaap	Payments For Leasing Costs PaymentsForLeasingCosts	29983	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	143896655	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80002625	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	29169017	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2717	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26752135	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26754852	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55921152	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26752135	USD
CY2020Q4	adma	Working Capital WorkingCapital	133800000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted under the Company’s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company’s deferred tax assets.</p>
CY2019Q4	adma	Accrued Rebates AccruedRebates	978786	USD
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1100000	USD
CY2019	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1000000.0	USD
CY2020	adma	Vesting Period VestingPeriod	four-year
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P10Y
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	734972	USD
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11777091	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7768511	shares
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	32044393	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	33381806	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	30293288	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14455665	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19197918	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5227263	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	81535599	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	53064734	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	50457032	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	37466273	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8863942	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5724956	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	41593090	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	31741317	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3200000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2400000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6084024	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3639903	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2444121	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6084024	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2924550	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3159474	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	715352	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	715352	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	715352	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	298065	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3210884	USD
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1899769	USD
CY2020Q4	adma	Accrued Rebates AccruedRebates	2604245	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	347091	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	828120	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	549356	USD
CY2020Q4	us-gaap	Liability Premium Deficiency Testing On Long Duration Contract Amount LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount	779660	USD
CY2019Q4	us-gaap	Liability Premium Deficiency Testing On Long Duration Contract Amount LiabilityPremiumDeficiencyTestingOnLongDurationContractAmount	69415	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	207262	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	636978	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	8365143	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4481395	USD
CY2020Q4	us-gaap	Notes Payable NotesPayable	100000000	USD
CY2019Q4	us-gaap	Notes Payable NotesPayable	72500000	USD
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-7031134	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	-4208837	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	92968866	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	68291163	USD
CY2020	adma	Perceptive Tranche I Note And Perceptive Tranche Ii Fees Paid PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid	30000000.0	USD
CY2020Q4	adma	Perceptive Tranche I Note And Perceptive Tranche Ii Fees Paid PerceptiveTrancheINoteAndPerceptiveTrancheIiFeesPaid	7100000	USD
CY2020Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.137	pure
CY2020Q4	us-gaap	Subordinated Long Term Debt SubordinatedLongTermDebt	0	USD
CY2019Q4	us-gaap	Subordinated Long Term Debt SubordinatedLongTermDebt	15000000	USD
CY2020Q4	adma	Subordinated Long Term Debt Discount SubordinatedLongTermDebtDiscount	0	USD
CY2019Q4	adma	Subordinated Long Term Debt Discount SubordinatedLongTermDebtDiscount	-91947	USD
CY2020Q4	adma	Subordinated Long Term Debt Net Of Debt Discount SubordinatedLongTermDebtNetOfDebtDiscount	0	USD
CY2019Q4	adma	Subordinated Long Term Debt Net Of Debt Discount SubordinatedLongTermDebtNetOfDebtDiscount	14908053	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104902888	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	59318355	shares
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	30655784	shares
CY2020Q1	adma	Underwritten Public Offering UnderwrittenPublicOffering	23500000	shares
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	82300000	USD
CY2020Q1	adma	Underwritten Public Offering UnderwrittenPublicOffering	3525000	shares
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12300000	USD
CY2020Q1	adma	Net Proceeds From The Issuance Of Common Stock NetProceedsFromTheIssuanceOfCommonStock	88700000	USD
CY2019Q2	adma	Underwritten Public Offering UnderwrittenPublicOffering	12937500	shares
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51800000	USD
CY2019Q2	adma	Net Proceeds From The Issuance Of Common Stock NetProceedsFromTheIssuanceOfCommonStock	48400000	USD
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6626	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	27787	shares
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4528160	shares
CY2020Q4	adma	Weighted Average Exercise Price Of Outstanding Warrants WeightedAverageExercisePriceOfOutstandingWarrants	2.82
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2138160	shares
CY2019Q4	adma	Weighted Average Exercise Price Of Outstanding Warrants WeightedAverageExercisePriceOfOutstandingWarrants	3.81
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2855122	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2650777	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020	adma	Description Tax Benefits DescriptionTaxBenefits	significant change in unrecognized tax benefits during the next 12 months
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2433142	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	66989523	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	47338300	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66989523	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	47338300	USD
CY2020	adma	Credit Facility Percentage CreditFacilityPercentage	0.10	pure
CY2020	adma	Plasma Supply Agreement Term PlasmaSupplyAgreementTerm	P10Y
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15907195	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-10138657	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3797393	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2010517	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	19535265	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11790031	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-246989	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-115086	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	416312	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	474229	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	59114928	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	42496374	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	921577	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	630516	USD
CY2020Q4	adma	Deferred Tax Assets Tax Credit Carryforwards Interest DeferredTaxAssetsTaxCreditCarryforwardsInterest	2911508	USD
CY2019Q4	adma	Deferred Tax Assets Tax Credit Carryforwards Interest DeferredTaxAssetsTaxCreditCarryforwardsInterest	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1080041	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1174733	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	563956	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	603535	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2397513	USD
CY2020	adma	Incremental Borrowing Rate IncrementalBorrowingRate	0.13	pure
CY2020	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	700000	USD
CY2020	adma	Cash Payments For Lease CashPaymentsForLease	500000	USD
CY2019	adma	Cash Payments For Lease CashPaymentsForLease	600000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4700000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1500000	USD
CY2020	adma	Weighted Average Remaining Term WeightedAverageRemainingTerm	P8Y8M12D
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	954133	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1031213	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1009159	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	871532	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	866475	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	3168953	USD
CY2020Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	7901465	USD
CY2020Q4	adma	Interest Portion Of Minimum Lease Payments InterestPortionOfMinimumLeasePayments	3201632	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	365682	USD
CY2020Q4	adma	Operating Lease Liability Total OperatingLeaseLiabilityTotal	4334151	USD
CY2020	adma	Lease Description LeaseDescription	With the exception of an advance deposit and an initial months’ rent totaling approximately $34,000, no payments were made under this lease during the year ended December 31, 2020. The initial term of the first lease is for 133 months, with monthly rental payments varying between approximately $13,000 and $17,000, including common area maintenance charges.
CY2020	adma	Compensation Expense CompensationExpense	900000	USD
CY2019	adma	Compensation Expense CompensationExpense	700000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	10267632	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8112231	USD
CY2019	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	973958	USD
CY2020	adma	Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities	514904	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3329374	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1421669	USD
CY2019	adma	Warrants Issued In Connection With Notes Payable WarrantsIssuedInConnectionWithNotesPayable	3740980	USD
CY2020	adma	Warrants Issued In Connection With Notes Payable WarrantsIssuedInConnectionWithNotesPayable	3579115	USD

Files In Submission

Name	View Source	Status
0001193805-21-000411-index-headers.html	Edgar Link	pending
0001193805-21-000411-index.html	Edgar Link	pending
0001193805-21-000411.txt	Edgar Link	pending
0001193805-21-000411-xbrl.zip	Edgar Link	pending
adma-20201231.xsd	Edgar Link	pending
adma-20201231_cal.xml	Edgar Link	unprocessable
adma-20201231_def.xml	Edgar Link	unprocessable
adma-20201231_lab.xml	Edgar Link	unprocessable
adma-20201231_pre.xml	Edgar Link	unprocessable
adma_10k.htm	Edgar Link	pending
adma_10k_htm.xml	Edgar Link	completed
adma_ex211.htm	Edgar Link	pending
adma_ex231.htm	Edgar Link	pending
adma_ex311.htm	Edgar Link	pending
adma_ex312.htm	Edgar Link	pending
adma_ex321.htm	Edgar Link	pending
adma_ex322.htm	Edgar Link	pending
adma_ex411.htm	Edgar Link	pending
adma_ex47.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADMA
ADMA Biologics Inc Stock $adma

2020 Q4 Form 10-K Financial Statement

#000119380521000411 Filed on March 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA ADMA Biologics Inc Stock $adma

2020 Q4 Form 10-K Financial Statement

#000119380521000411 Filed on March 25, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADMA
ADMA Biologics Inc Stock $adma